The integrated pharmaceutical entity in India spans the pharmaceutical value chain with services in research, development, manufacturing, distribution, marketing, and exports. It's set to launch an IPO for equity shares with a face value of ₹10, priced between ₹426 and ₹448, totaling ₹570 crore at the upper band. The IPO runs from December 21 to December 26, 2023.